Literature DB >> 20531187

The pathology of and controversial aspects of ovarian borderline tumours.

W Glenn McCluggage1.   

Abstract

PURPOSE OF REVIEW: Ovarian borderline tumours are relatively uncommon, but not rare, neoplasms. Pathologists and oncologists often struggle with various aspects of borderline tumours which are sometimes controversial and poorly understood. RECENT
FINDINGS: In this review, I discuss pathological and clinical aspects of ovarian borderline tumours of the two most common types, serous and mucinous, these having a different natural behaviour. The recent literature is reviewed as well as important papers prior to this. Controversial aspects covered include the relationship between borderline tumours and carcinomas, the significance of microinvasion, the significance of a micropapillary architecture in serous borderline tumours, the diagnostic criteria for and significance of extraovarian 'implants', lymph node involvement, staging issues and tumour behaviour.
SUMMARY: Ovarian borderline tumours have an excellent prognosis, although a small percentage is associated with the development of progressive disease. It has been suggested that the term borderline tumour should be abandoned but it is argued that this terminology should be retained for both serous and mucinous neoplasms because of the risk of extraovarian implants in serous borderline tumours and the large size and heterogeneity of mucinous borderline tumours which may result in an invasive focus being undetected by the pathologist.

Entities:  

Mesh:

Year:  2010        PMID: 20531187     DOI: 10.1097/CCO.0b013e32833b0dc1

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  11 in total

1.  FGF18 as a potential biomarker in serous and mucinous ovarian tumors.

Authors:  Saba El-Gendi; Eman Abdelzaher; Mohamed Farouk Mostafa; Ghada Abu Sheasha
Journal:  Tumour Biol       Date:  2015-10-02

2.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

3.  Significance of lymph node ratio on survival of women with borderline ovarian tumors.

Authors:  David J Nusbaum; Rachel S Mandelbaum; Hiroko Machida; Shinya Matsuzaki; Lynda D Roman; Anil K Sood; David M Gershenson; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2020-04-17       Impact factor: 2.344

4.  A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.

Authors:  Cristina Anton; Filomena Marino Carvalho; Elci Isabel Oliveira; Gustavo Arantes Rosa Maciel; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 5.  Recent concepts of ovarian carcinogenesis: type I and type II.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

6.  Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry.

Authors:  Jung Min Park; Min Kyu Kim
Journal:  J Menopausal Med       Date:  2014-04-28

Review 7.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

8.  Minimal apparent diffusion coefficient value of the solid component to differentiate borderline and malignant ovarian epithelial tumours: a preliminary report.

Authors:  Sahat B R E Matondang; Avrilia Ekawati; Hartono Tjahjadi; Joedo Prihartono
Journal:  Pol J Radiol       Date:  2020-05-13

9.  Outcomes of fertility-sparing surgery for stage II and III serous borderline ovarian tumors.

Authors:  Ziyang Lu; Bin Li; Chao Gu
Journal:  J Int Med Res       Date:  2019-08-21       Impact factor: 1.671

10.  KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

Authors:  Sabine Heublein; Katinka Grasse; Harald Hessel; Alexander Burges; Miriam Lenhard; Jutta Engel; Thomas Kirchner; Udo Jeschke; Doris Mayr
Journal:  BMC Cancer       Date:  2013-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.